1. Introduction {#sec1-ijms-21-02437}
===============

Recently, we demonstrated that history of pregnancy-related complications, such as gestational hypertension (GH), preeclampsia (PE), and/or fetal growth restriction (FGR), was associated with postpartum epigenetic changes characteristic for cardiovascular and cerebrovascular diseases \[[@B1-ijms-21-02437],[@B2-ijms-21-02437],[@B3-ijms-21-02437]\].

We showed that previous occurrence of either GH, PE, and/or FGR might predispose a proportion of women to later development of cardiovascular and cerebrovascular diseases due to the presence of alterations in the expression of cardiovascular and cerebrovascular disease-associated microRNAs in their whole peripheral blood \[[@B1-ijms-21-02437],[@B2-ijms-21-02437],[@B3-ijms-21-02437]\].

Gestational diabetes mellitus (GDM) is defined as carbohydrate intolerance that develops during pregnancy, usually during second or third trimester of gestation \[[@B4-ijms-21-02437]\]. Women with GDM have an increased risk of developing diabetes (predominantly type 2 diabetes) later in life. It is estimated that up to 70% of women with GDM will develop diabetes within 22--28 years after pregnancy \[[@B4-ijms-21-02437],[@B5-ijms-21-02437],[@B6-ijms-21-02437],[@B7-ijms-21-02437]\].

The incidence of GDM increases with the same risk factors seen for type 2 diabetes such as obesity, sedentary lifestyle, and increasing reproductive age of women \[[@B4-ijms-21-02437],[@B5-ijms-21-02437],[@B6-ijms-21-02437],[@B7-ijms-21-02437]\].

The initial criteria for diagnosis of GDM were established more than 40 years ago to identify women at a high risk for development of diabetes after pregnancy \[[@B8-ijms-21-02437],[@B9-ijms-21-02437],[@B10-ijms-21-02437]\]. The two-step screening approach to testing for GDM is currently recommended by The American College of Obstetricians and Gynecologists \[[@B4-ijms-21-02437]\] and The International Association of Diabetes and Pregnancy Study Groups (IADPSG) \[[@B10-ijms-21-02437]\]. Overall, using the proposed IADPSG criteria, 18% of pregnant women in the United States are identified as having GDM \[[@B10-ijms-21-02437]\].

The goal of the current study was to evaluate the risk of later development of diabetes mellitus, and cardiovascular and cerebrovascular diseases based on an epigenetic profile of cardiovascular/cerebrovascular disease associated microRNAs in whole peripheral blood of young and middle-aged mothers with a history of gestational diabetes mellitus (GDM) 3--11 years after the delivery. The hypothesis of the assessment of cardiovascular risk in women was based on the knowledge that a series of microRNAs play a role in the pathogenesis of diabetes mellitus and cardiovascular/cerebrovascular diseases ([Table 1](#ijms-21-02437-t001){ref-type="table"}) \[[@B11-ijms-21-02437],[@B12-ijms-21-02437],[@B13-ijms-21-02437],[@B14-ijms-21-02437],[@B15-ijms-21-02437],[@B16-ijms-21-02437],[@B17-ijms-21-02437],[@B18-ijms-21-02437],[@B19-ijms-21-02437],[@B20-ijms-21-02437],[@B21-ijms-21-02437],[@B22-ijms-21-02437],[@B23-ijms-21-02437],[@B24-ijms-21-02437],[@B25-ijms-21-02437],[@B26-ijms-21-02437],[@B27-ijms-21-02437],[@B28-ijms-21-02437],[@B29-ijms-21-02437],[@B30-ijms-21-02437],[@B31-ijms-21-02437],[@B32-ijms-21-02437],[@B33-ijms-21-02437],[@B34-ijms-21-02437],[@B35-ijms-21-02437],[@B36-ijms-21-02437],[@B37-ijms-21-02437],[@B38-ijms-21-02437],[@B39-ijms-21-02437],[@B40-ijms-21-02437],[@B41-ijms-21-02437],[@B42-ijms-21-02437],[@B43-ijms-21-02437],[@B44-ijms-21-02437],[@B45-ijms-21-02437],[@B46-ijms-21-02437],[@B47-ijms-21-02437],[@B48-ijms-21-02437],[@B49-ijms-21-02437],[@B50-ijms-21-02437],[@B51-ijms-21-02437],[@B52-ijms-21-02437],[@B53-ijms-21-02437],[@B54-ijms-21-02437],[@B55-ijms-21-02437],[@B56-ijms-21-02437],[@B57-ijms-21-02437],[@B58-ijms-21-02437],[@B59-ijms-21-02437],[@B60-ijms-21-02437],[@B61-ijms-21-02437],[@B62-ijms-21-02437],[@B63-ijms-21-02437],[@B64-ijms-21-02437],[@B65-ijms-21-02437],[@B66-ijms-21-02437],[@B67-ijms-21-02437],[@B68-ijms-21-02437],[@B69-ijms-21-02437],[@B70-ijms-21-02437],[@B71-ijms-21-02437],[@B72-ijms-21-02437],[@B73-ijms-21-02437],[@B74-ijms-21-02437],[@B75-ijms-21-02437],[@B76-ijms-21-02437],[@B77-ijms-21-02437],[@B78-ijms-21-02437],[@B79-ijms-21-02437],[@B80-ijms-21-02437],[@B81-ijms-21-02437],[@B82-ijms-21-02437],[@B83-ijms-21-02437],[@B84-ijms-21-02437],[@B85-ijms-21-02437],[@B86-ijms-21-02437],[@B87-ijms-21-02437],[@B88-ijms-21-02437],[@B89-ijms-21-02437],[@B90-ijms-21-02437],[@B91-ijms-21-02437],[@B92-ijms-21-02437],[@B93-ijms-21-02437],[@B94-ijms-21-02437],[@B95-ijms-21-02437],[@B96-ijms-21-02437],[@B97-ijms-21-02437],[@B98-ijms-21-02437],[@B99-ijms-21-02437],[@B100-ijms-21-02437],[@B101-ijms-21-02437],[@B102-ijms-21-02437],[@B103-ijms-21-02437],[@B104-ijms-21-02437],[@B105-ijms-21-02437],[@B106-ijms-21-02437],[@B107-ijms-21-02437],[@B108-ijms-21-02437],[@B109-ijms-21-02437],[@B110-ijms-21-02437],[@B111-ijms-21-02437],[@B112-ijms-21-02437],[@B113-ijms-21-02437],[@B114-ijms-21-02437],[@B115-ijms-21-02437],[@B116-ijms-21-02437],[@B117-ijms-21-02437],[@B118-ijms-21-02437],[@B119-ijms-21-02437],[@B120-ijms-21-02437],[@B121-ijms-21-02437],[@B122-ijms-21-02437],[@B123-ijms-21-02437],[@B124-ijms-21-02437],[@B125-ijms-21-02437],[@B126-ijms-21-02437],[@B127-ijms-21-02437],[@B128-ijms-21-02437],[@B129-ijms-21-02437],[@B130-ijms-21-02437],[@B131-ijms-21-02437],[@B132-ijms-21-02437],[@B133-ijms-21-02437],[@B134-ijms-21-02437],[@B135-ijms-21-02437],[@B136-ijms-21-02437],[@B137-ijms-21-02437],[@B138-ijms-21-02437],[@B139-ijms-21-02437],[@B140-ijms-21-02437],[@B141-ijms-21-02437],[@B142-ijms-21-02437],[@B143-ijms-21-02437],[@B144-ijms-21-02437],[@B145-ijms-21-02437],[@B146-ijms-21-02437],[@B147-ijms-21-02437],[@B148-ijms-21-02437],[@B149-ijms-21-02437],[@B150-ijms-21-02437],[@B151-ijms-21-02437],[@B152-ijms-21-02437],[@B153-ijms-21-02437],[@B154-ijms-21-02437],[@B155-ijms-21-02437],[@B156-ijms-21-02437],[@B157-ijms-21-02437],[@B158-ijms-21-02437],[@B159-ijms-21-02437],[@B160-ijms-21-02437],[@B161-ijms-21-02437],[@B162-ijms-21-02437],[@B163-ijms-21-02437],[@B164-ijms-21-02437],[@B165-ijms-21-02437],[@B166-ijms-21-02437],[@B167-ijms-21-02437],[@B168-ijms-21-02437],[@B169-ijms-21-02437],[@B170-ijms-21-02437]\].

Postpartal epigenetic profiling of microRNAs (miR-1-3p, miR-16-5p, miR-17-5p, miR-20a-5p, miR-20b-5p, miR-21-5p, miR-23a-3p, miR-24-3p, miR-26a-5p, miR-29a-3p, miR-92a-3p, miR-100-5p, miR-103a-3p, miR-125b-5p, miR-126-3p, miR-130b-3p, miR-133a-3p, miR-143-3p, miR-145-5p, miR-146a-5p, miR-155-5p, miR-181a-5p, miR-195-5p, miR-199a-5p, miR-210-3p, miR-221-3p, miR-342-3p, miR-499a-5p, and miR-574-3p) known to be involved in the onset of insulin resistance and diabetes, dyslipidemia, hypertension, vascular inflammation, atherosclerosis, angiogenesis, coronary artery disease, myocardial infarction and heart failure, stroke, intracranial aneurysm, pulmonary arterial hypertension, and peripartum cardiomyopathy was the subject of our interest.

MicroRNAs, small noncoding RNAs, are known to regulate gene expression at the posttranscriptional level by blocking translation or degrading of target messenger RNA \[[@B171-ijms-21-02437]\].

To the best of our present knowledge, no study on expression profiling of microRNAs associated with diabetes mellitus, and cardiovascular and cerebrovascular diseases in whole peripheral blood of mothers after pregnancies affected by gestational diabetes mellitus has been carried out.

2. Results {#sec2-ijms-21-02437}
==========

MicroRNA gene expression was compared between mothers after normal and GDM-complicated pregnancies in maternal whole peripheral blood 3 to 11 years postpartum. Just the results, when the complicated cases reached a statistical significance, are presented below.

2.1. Expression Profile of MicroRNAs Associated with Diabetes Mellitus and Cardiovascular/Cerebrovascular Diseases in Mothers after GDM Pregnancies {#sec2dot1-ijms-21-02437}
---------------------------------------------------------------------------------------------------------------------------------------------------

The expression of miR-1-3p (*p* \< 0.001), miR-16-5p (*p* \< 0.001), miR-17-5p (*p* \< 0.001), miR-20a-5p (*p* \< 0.001), miR-20b-5p (*p* \< 0.001), miR-21-5p (*p* \< 0.001), miR-23a-3p (*p* \< 0.001), miR-24-3p (*p* = 0.007), miR-26a-5p (*p* \< 0.001), miR-29a-3p (*p* \< 0.001), miR-100-5p (*p* \< 0.001), miR-103a-3p (*p* \< 0.001), miR-125b-5p (*p* \< 0.001), miR-126-3p (*p* \< 0.001), miR-130b-3p (*p* \< 0.001), miR-133a-3p (*p* \< 0.001), miR-143-3p (*p* \< 0.001), miR-145-5p (*p* = 0.002), miR-146a-5p (*p* \< 0.001), miR-181a-5p (*p* \< 0.001), miR-195-5p (*p* \< 0.001), miR-199a-5p (*p* \< 0.001), miR-221-3p (*p* \< 0.001), miR-342-3p (*p* = 0.003), miR-499a-5p (*p* \< 0.001), and miR-574-3p (*p* \< 0.001) differed significantly between the control group and women previously affected with GDM. These microRNAs were upregulated in GDM-affected patients ([Figure 1](#ijms-21-02437-f001){ref-type="fig"} and [Figure 2](#ijms-21-02437-f002){ref-type="fig"}).

The ROC curve analysis confirmed a significant upregulation of these particular microRNAs for mothers with a history of GDM when the comparison to the controls was performed ([Figure 1](#ijms-21-02437-f001){ref-type="fig"}).

The very good sensitivity at 10.0% FPR for miR-1-3p (43.24%), miR-16-5p (20.72%), miR-17-5p (21.62%), miR-20b-5p (38.74%), miR-21-5p (28.83%), miR-23a-3p (17.12%), miR-26a-5p (20.72%), miR-29a-3p (21.62%), miR-103a-3p (30.63%), miR-133a-3p (18.92%), miR-146a-5p (17.12%), miR-181a-5p (31.53%), miR-195-5p (16.22%), miR-199a-5p (15.32%), miR-221-3p (31.53%), and miR-499a-5p (28.83%) is found ([Figure 2](#ijms-21-02437-f002){ref-type="fig"}).

However, despite the upregulation of microRNAs, the poor sensitivity at 10.0% FPR for miR-20a-5p (10.81%), miR-24-3p (0.90%), miR-100-5p (13.51%), miR-125b-5p (9.91%), miR-126-3p (9.91%), miR-130b-3p (3.60%), miR-143-3p (13.51%), miR-145-5p (7.21%), miR-342-3p (1.8%), and miR-574-3p (10.81%) was detected, therefore, these particular microRNAs were not further used for diabetes mellitus and cardiovascular risk assessment in mothers previously affected with GDM ([Figure 2](#ijms-21-02437-f002){ref-type="fig"}).

Combined screening of miR-1-3p, miR-16-5p, miR-17-5p, miR-20b-5p, miR-21-5p, miR-23a-3p, miR-26a-5p, miR-29a-3p, miR-103a-3p, miR-133a-3p, miR-146a-5p, miR-181a-5p, miR-195-5p, miR-199a-5p, miR-221-3p, and miR-499a-5p showed the highest accuracy for mothers with a prior exposure to GDM (AUC 0.900, *p* \< 0.001, sensitivity 77.48%, specificity 93.26%, cut off \> 0.611270413). It was able to identify 77.48% of mothers with an increased cardiovascular risk at 10.0% FPR ([Figure 3](#ijms-21-02437-f003){ref-type="fig"}).

2.2. Expression Profile of MicroRNAs Associated with Diabetes Mellitus and Cardiovascular/Cerebrovascular Diseases in Mothers after GDM Pregnancies with Regard to the Treatment Strategies (Diet Only and/or Diet and Therapy) {#sec2dot2-ijms-21-02437}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Concurrently, it was observed that the expression of miR-1-3p (*p* \< 0.001, *p* = 0.013), miR-16-5p (*p* \< 0.001, *p* = 0.057), miR-17-5p (*p* \< 0.001, *p* = 0.035), miR-20b-5p (*p* \< 0.001, *p* = 0.002), miR-21-5p (*p* \< 0.001, *p* \< 0.001), miR-23a-3p (*p* \< 0.001, *p* = 0.096), miR-26a-5p (*p* \< 0.001, *p* = 0.002), miR-29a-3p (*p* \< 0.001, *p* \< 0.001), miR-103a-3p (*p* \< 0.001, *p* = 0.001), miR-146a-5p (*p* \< 0.001, *p* = 0.019), miR-181a-5p (*p* \< 0.001, *p* = 0.003), miR-195-5p (*p* \< 0.001, *p* \< 0.001), miR-199a-5p (*p* \< 0.001, *p* = 0.002), miR-221-3p (*p* \< 0.001, *p* \< 0.001), and miR-499a-5p (*p* \< 0.001, *p* \< 0.001) differed significantly or showed a trend toward statistical significance between the groups of mothers affected with GDM regardless of the treatment strategies (diet only and/or the combination of diet and therapy) and the controls ([Figure 4](#ijms-21-02437-f004){ref-type="fig"}). Nevertheless, miR-133a-3p was upregulated just in the group of patients previously affected with GDM on diet only (*p* = 0.001) ([Figure 4](#ijms-21-02437-f004){ref-type="fig"}).

Due to a low number of women on the diet and therapy (*n* = 18) in our studied group of patients previously affected with GDM, we decided not to perform ROC curve analysis for particular groups of patients regarding the GDM treatment strategies (diet only and/or combination of diet and therapy).

No difference in microRNA expression profiles was observed between the groups of mothers with a history of GDM on diet only and on the combination of diet and therapy (*p* = 1.0 for nearly all examined microRNAs).

2.3. Information on MicroRNA-Gene-Biological Pathway Interactions {#sec2dot3-ijms-21-02437}
-----------------------------------------------------------------

The extensive file of predicted targets of all microRNAs aberrantly expressed in whole peripheral blood of mothers with a history of GDM indicates that a large group of genes is involved in biological pathways related to insulin signaling, type 1 diabetes mellitus, and type 2 diabetes mellitus ([Table 2](#ijms-21-02437-t002){ref-type="table"}, [Table 3](#ijms-21-02437-t003){ref-type="table"} and [Table 4](#ijms-21-02437-t004){ref-type="table"}).

3. Discussion {#sec3-ijms-21-02437}
=============
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As expected, the expression profile of microRNAs differed between mothers affected with GDM and controls. Abnormal expression profile of multiple microRNAs was found in mothers with a history of GDM (26/29 studied microRNAs: miR-1-3p, miR-16-5p, miR-17-5p, miR-20a-5p, miR-20b-5p, miR-21-5p, miR-23a-3p, miR-24-3p, miR-26a-5p, miR-29a-3p, miR-100-5p, miR-103a-3p, miR-125b-5p, miR-126-3p, miR-130b-3p, miR-133a-3p, miR-143-3p, miR-145-5p, miR-146a-5p, miR-181a-5p, miR-195-5p, miR-199a-5p, miR-221-3p, miR-342-3p, miR-499a-5p, and miR-574-3p).

Nevertheless, when the ROC curve analysis was performed, only 16/26 microRNAs (miR-1-3p, miR-16-5p, miR-17-5p, miR-20b-5p, miR-21-5p, miR-23a-3p, miR-26a-5p, miR-29a-3p, miR-103a-3p, miR-133a-3p, miR-146a-5p, miR-181a-5p, miR-195-5p, miR-199a-5p, miR-221-3p, and miR-499a-5p) with aberrant postpartal expression profile in whole peripheral blood of mothers with a prior exposure to GDM showed a higher sensitivity, ranging from 15.32% to 43.24%, at 10.0% FPR.

Screening based on the combination of these particular microRNAs was superior over using individual microRNAs, since it showed the highest accuracy for mothers with a history of GDM (AUC 0.900, *p* \< 0.001, sensitivity 77.48%, specificity 93.26%, cut off \> 0.611270413). It was able to identify 77.48% mothers with an increased cardiovascular risk at 10.0% FPR.

Subsequently, epigenetic profile was compared between groups with regard to the treatment strategy (GDM on diet only, GDM on the combination of diet and therapy). The upregulation or trend towards upregulation of almost all studied microRNAs (with the exception of miR-133a-3p) was present in both groups of mothers affected with GDM regardless of the treatment strategies.

Previously, we demonstrated that pregnancy-related complications, such as gestational hypertension, preeclampsia, and/or fetal growth restriction, were associated with postpartum alterations in gene expression of cardiovascular/cerebrovascular disease-associated microRNAs \[[@B1-ijms-21-02437],[@B2-ijms-21-02437],[@B3-ijms-21-02437]\].

Likewise, a previous occurrence of GH, as well as a previous occurrence of GDM, was associated with the upregulation of miR-20a-5p, miR-143-3p, miR-146a-5p, miR-181a-5p, miR-199a-5p, miR-221-3p, and miR-499a-5p \[[@B1-ijms-21-02437],[@B2-ijms-21-02437],[@B3-ijms-21-02437]\].

Moreover, the compilation of data resulting from our previous and current studies showed that the upregulation of miR-17-5p, miR-20b-5p, miR-29a-3p, and miR-126-3p was a mutual phenomenon observed in women with a prior exposure to GH, severe PE, and/or GDM \[[@B1-ijms-21-02437],[@B2-ijms-21-02437],[@B3-ijms-21-02437]\].

In addition, a history of GH, early PE, and/or GDM was associated with postpartal upregulation of miR-1-3p and miR-17-5p. Parallel, women affected with GH and/or late PE showed similar postpartal expression profile (upregulation of miR-17-5p, miR-20b-5p, and miR-29a-3p) as women with a history of GDM \[[@B1-ijms-21-02437],[@B2-ijms-21-02437],[@B3-ijms-21-02437]\].

Alike, as in women affected with severe PE and/or early PE, upregulation of miR-133a-3p was also present in women affected with GDM. Moreover, a history of severe PE and/or GDM was associated with upregulation of miR-130b-3p \[[@B1-ijms-21-02437],[@B2-ijms-21-02437],[@B3-ijms-21-02437]\].

Furthermore, women with a history of GDM demonstrated upregulation of miR-100-5p, miR-125b-5p, miR-133a-3p, and miR-145-5p as women with prior exposure to PE and/or FGR with abnormal Doppler parameters \[[@B1-ijms-21-02437],[@B2-ijms-21-02437],[@B3-ijms-21-02437]\].

On the other hand, our study revealed that upregulation of miR-16-5p, miR-21-5p, miR-23a-3p, miR-24-3p, miR-26a-5p, miR-103a-3p, miR-195-5p, miR-342-3p, and miR-574-3p represented a unique feature of aberrant expression profile of women with a prior exposure to GDM.

Interestingly, interaction network analysis via Cytoscale V.3.6.1 revealed that miR-145-5p together with miR-875-5p are upregulated microRNAs that target the most genes in gestational diabetes mellitus \[[@B125-ijms-21-02437]\].

In addition, increased expression of miR-126-3p and miR-130b-3p was observed in human umbilical vein endothelial cells (HUVECs) derived from GDM patients \[[@B98-ijms-21-02437]\].

Moreover, a set of circulating microRNAs associated with cardiovascular/cerebrovascular diseases (miR-16-5p, miR-17-5p, miR-20a-5p, miR-29a-3p, miR-125b-5p, and miR-195-5p) was reported by several independent studies \[[@B20-ijms-21-02437],[@B21-ijms-21-02437],[@B80-ijms-21-02437],[@B92-ijms-21-02437],[@B143-ijms-21-02437],[@B172-ijms-21-02437],[@B173-ijms-21-02437]\] to be upregulated during various gestational ages in serum or plasma of mothers with already-diagnosed GDM or mothers who were destined to develop GDM later during pregnancy. The data resulting from these prenatally ongoing studies and interaction network analysis \[[@B20-ijms-21-02437],[@B21-ijms-21-02437],[@B80-ijms-21-02437],[@B92-ijms-21-02437],[@B98-ijms-21-02437],[@B125-ijms-21-02437],[@B143-ijms-21-02437],[@B172-ijms-21-02437],[@B173-ijms-21-02437]\] may support our current finding referring to upregulated expression profile of these particular microRNAs in whole peripheral blood of women with a prior exposure to GDM.

In addition, from the portfolio of microRNAs we tested, just miR-16-5p, miR-17-5p, miR-20a-5p, and miR-29a were identified by other investigators as the most promising biomarkers of GDM or the best predictors of GDM, respectively \[[@B21-ijms-21-02437],[@B173-ijms-21-02437]\], which is consistent with our current finding, since during the course of postpartum screening, miR-16-5p (20.72%), miR-17-5p (21.62%), and miR-29a-3p (21.62%) upregulation persisted in a larger proportion of women with a prior exposure to GDM.

In compliance with our study, which showed a low sensitivity of miR-20a-5p (10.81%) to select women with a higher cardiovascular risk after GDM gestation based on its upregulated profile, miR-20a-5p also added little value as the predictor of GDM due to its low predictive value based on its upregulated profile (ROC, AUC just 0.740) \[[@B21-ijms-21-02437],[@B173-ijms-21-02437]\].

This study demonstrated that the dysregulation of at least four microRNAs (miR-16-5p, miR-17-5p, miR-29a-3p, and miR-195-5p) induced by GDM-complicated pregnancy in maternal circulation (plasma or serum) is present as well in circulation (whole peripheral blood) of a larger proportion of mothers (20.72%, 21.62%, 21.62%, 16.22%) with hindsight (3 to 11 years after the delivery) after the exposure to GDM.

It is obvious that changes in epigenome induced by GDM, which are persistently present in maternal circulation, may cause later development of diabetes mellitus and cardiovascular and cerebrovascular diseases in women with a prior exposure to GDM.

However, most of microRNAs, which were the subjects of our interest, have not yet been observed by other investigators to be dysregulated in maternal circulation (peripheral blood, plasma, or serum samples) of women with clinically established GDM or before the onset of GDM \[[@B20-ijms-21-02437],[@B21-ijms-21-02437],[@B37-ijms-21-02437],[@B80-ijms-21-02437],[@B92-ijms-21-02437],[@B143-ijms-21-02437],[@B149-ijms-21-02437],[@B172-ijms-21-02437],[@B173-ijms-21-02437],[@B174-ijms-21-02437],[@B175-ijms-21-02437],[@B176-ijms-21-02437]\]. So, it is feasible that epigenetic profiles of a series of microRNAs have also been changing with time by force of various circumstances as a result of the interaction between genetic and environmental factors \[[@B177-ijms-21-02437]\].

4. Materials and Methods {#sec4-ijms-21-02437}
========================

4.1. Participants {#sec4dot1-ijms-21-02437}
-----------------

The study included a prospectively collected cohort of Caucasian mothers with a history of GDM (*n* = 111) and age-matched mothers after normal course of gestation (*n* = 89). In-person visit was conducted 3--11 years after the pregnancy ended. Of the 111 GDM pregnancies, 93 were on diet only and 18 were on the combination of diet and therapy (17 patients required insulin administration and in 1 patient metformin, an oral hypoglycemic agent, was prescribed).

The clinical characteristics of mothers after GDM-complicated pregnancies are presented in [Table 5](#ijms-21-02437-t005){ref-type="table"}, [Table 6](#ijms-21-02437-t006){ref-type="table"} and [Table 7](#ijms-21-02437-t007){ref-type="table"}.

Gestational diabetes mellitus is defined as any degree of glucose intolerance with onset or first recognition during pregnancy \[[@B10-ijms-21-02437],[@B178-ijms-21-02437],[@B179-ijms-21-02437]\]. The International Association of Diabetes and Pregnancy Study Groups' (IADPSG) recommendations on the diagnosis and classification of hyperglycemia in pregnancy were followed \[[@B10-ijms-21-02437]\]. The first screening phase detects, during the first trimester of gestation, women with overt diabetes (fasting plasma glucose level is ≥7.0 mmol/L) and women with GDM (fasting plasma glucose level ≥ 5.1 mmol/L \< 7.0 mmol/L). The second screening phase, 2-h 75-g OGTT, at 24--28 weeks of gestation is done in all women not previously found to have overt diabetes or GDM, and identifies GDM if fasting plasma glucose level is ≥5.1 mmol/L or 1-h plasma glucose is ≥10.0 mmol/L or 2-h plasma glucose is ≥8.5 mmol/L \[[@B10-ijms-21-02437]\].

Patients demonstrating other pregnancy-related complications, such as gestational hypertension, preeclampsia, fetal growth restriction, premature rupture of membranes, in utero infections, fetal anomalies or chromosomal abnormalities, and fetal demise in utero or stillbirth, were not involved in the study.

Written informed consent was provided for all participants included in the study. The study was approved by the Ethics Committee of the Institute for the Care of the Mother and Child, Prague, Czech Republic (grant no. AZV 16-27761A, long-term monitoring of complex cardiovascular profile in the mother, fetus, and offspring descending from pregnancy-related complications, date of approval: 28 May 2015) and by the Ethics Committee of the Third Faculty of Medicine, Prague, Czech Republic (grant no. AZV 16-27761A, long-term monitoring of complex cardiovascular profile in the mother, fetus, and offspring descending from pregnancy-related complications, date of approval: 27 March 2014).

4.2. Processing of Samples {#sec4dot2-ijms-21-02437}
--------------------------

Homogenized cell lysates were prepared immediately after collection of whole peripheral blood samples (EDTA tubes, 200 µL) using QIAamp RNA Blood Mini Kit (Qiagen, Hilden, Germany, no: 52304).

Total RNA was extracted from homogenized cell lysates stored at −80 °C using a mirVana microRNA Isolation kit (Ambion, Austin, USA, no: AM1560) and followed by an enrichment procedure for small RNAs. To minimize DNA contamination, the eluted RNA was treated for 30 min at 37 °C with 5 µL of DNase I (Thermo Fisher Scientific, CA, USA, no: EN0521). A RNA fraction highly enriched in short RNAs (\< 200 nt) was obtained. The concentration and quality of RNA was assessed using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, USA). If the A(260/280) absorbance ratio of isolated RNA was 1.8--2.0 and the A(260/230) absorbance ratio was greater than 1.6, the RNA fraction was pure and used for the consecutive analysis.

4.3. Reverse Transcriptase Reaction {#sec4dot3-ijms-21-02437}
-----------------------------------

Individual microRNAs were reverse transcribed into complementary DNA (cDNA) in a total reaction volume of 10 µL using microRNA-specific stem-loop RT primers, components of TaqMan MicroRNA Assays ([Table 8](#ijms-21-02437-t008){ref-type="table"}), and TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, Branchburg, USA, no: 4366597). Reverse transcriptase reactions were performed with the following thermal cycling parameters: 30 min at 16 °C, 30 min at 42 °C, 5 min at 85 °C, and then held at 4 °C using a 7500 Real-Time PCR system (Applied Biosystems, Branchburg, USA).

4.4. Relative Quantification of MicroRNAs by Real-Time PCR {#sec4dot4-ijms-21-02437}
----------------------------------------------------------

The cDNA (3 µL) was mixed with specific TaqMan MGB probes and primers (TaqMan MicroRNA Assay, Applied Biosystems, Branchburg, USA), and the components of the TaqMan Universal PCR Master Mix (Applied Biosystems, Branchburg, USA, no: 4318157). A total reaction volume was 15 µL. TaqMan PCR conditions were set up as described in the TaqMan guidelines for a 7500 Real-Time PCR system. All PCRs were performed in duplicates with the involvement of multiple negative controls such as NTC (water instead of cDNA sample), NAC (nontranscribed RNA samples), and genomic DNA (isolated from equal biological samples), which did not generate any signal during PCR reactions. The samples were considered positive if the amplification signal occurred at Ct \< 40 (before the 40th threshold cycle).

The expression of particular microRNA was determined using the comparative Ct method \[[@B180-ijms-21-02437]\] relative to normalization factor (geometric mean of two selected endogenous controls) \[[@B181-ijms-21-02437]\]. Two noncoding small nucleolar RNAs (RNU58A and RNU38B) were optimal for qPCR data normalization in this setting. They demonstrated equal expression between children descending from normal and complicated pregnancies. RNU58A and RNU38B also served as positive controls for successful extraction of RNA from all samples and were used as internal controls for variations during the preparation of RNA, cDNA synthesis, and real-time PCR.

A reference sample, RNA fraction highly enriched for small RNAs isolated from the fetal part of one randomly selected placenta derived from gestation with normal course, was used throughout the study for relative quantification.

4.5. Statistical Analysis {#sec4dot5-ijms-21-02437}
-------------------------

Data normality was assessed using the Shapiro--Wilk test \[[@B182-ijms-21-02437]\]. Since our experimental data did not follow a normal distribution, microRNA levels were compared between groups using the Kruskal--Wallis one-way analysis of variance with post hoc test for the comparison among multiple groups. The significance level was established at a *p*-value of p \< 0.05.

Receivers operating characteristic (ROC) curves were constructed to calculate the area under the curve (AUC) and the best cut-off point for particular microRNA was used in order to calculate the respective sensitivity at 90.0% specificity (MedCalc Software bvba, Ostend, Belgium). For every possible threshold or cut-off value, the MedCalc program reports the sensitivity, specificity, likelihood ratio positive (LR+), likelihood ratio negative (LR−).

To select the optimal combinations of microRNA biomarkers, logistic regression was used (MedCalc Software bvba, Ostend, Belgium). The logistic regression procedure allowed us to analyses the relationship between one dichotomous dependent variable and one or more independent variables. Another method to evaluate the logistic regression model makes use of ROC curve analysis. In this analysis, the power of the model's predicted values to discriminate between positive and negative cases is quantified by the area under the ROC curve (AUC). To perform a full ROC curve analysis, the predicted probabilities are first saved and next used as a new variable in ROC curve analysis. The dependent variable used in logistic regression then acts as the classification variable in the ROC curve analysis dialog box.

Box plots encompassing the median (dark horizontal line) of log-normalized gene expression values for particular microRNAs were generated using Statistica software (version 9.0; StatSoft, Inc., USA). The upper and lower limits of the boxes represent the 75th and 25th percentiles, respectively. The upper and lower whiskers indicate the maximum and minimum values that are no more than 1.5 times the span of the interquartile range (range of the values between the 25th and the 75th percentiles). Outliers are marked by circles and extremes by asterisks.

4.6. Information on MicroRNA-Gene-Biological Pathway Interactions {#sec4dot6-ijms-21-02437}
-----------------------------------------------------------------

MiRWalk database (available: <http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/>) and the Predicted Target module were used to provide information on predicted targets of those microRNAs that have been found to be dysregulated in whole peripheral blood of patients with a history of GDM. Only those predicted targets involved in particular human biological pathways (insulin signaling pathway, type 1 diabetes mellitus pathway, and type 2 diabetes mellitus pathway) are reported \[[@B183-ijms-21-02437]\].

MiRWalk is a comprehensive database that provides information on microRNAs from human, mouse, and rat on their predicted and/or validated target genes. MiRWalk2.0 not only documents miRNA binding sites within the complete sequence of a gene, but also combines this information with a comparison of binding sites resulting from 12 existing miRNA-target prediction programs (DIANA-microTv4.0, DIANA-microT-CDS, miRanda, mirBridge, miRDB4.0, miRmap, miRNAMap, DoRiNA, PicTar2, PITA, RNA22v2, RNAhybrid2.1, and Targetscan6.2) to build novel comparative platforms of binding sites for the promoter (4 prediction datasets), cds (5 prediction datasets), 5'- (5 prediction datasets), and 3'-UTR (13 prediction datasets) regions. Information on miRNA-target interactions on 2035 disease ontologies (DO), 6727 human phenotype ontologies (HPO) and 4980 OMIM disorders is available. It provides possible interactions between microRNAs and genes associated with 597 KEGG, 456 Panther, and 522 Wiki pathways.

5. Conclusions {#sec5-ijms-21-02437}
==============

In conclusion, epigenetic changes characteristic for diabetes mellitus and cardiovascular/cerebrovascular diseases are also present in whole peripheral blood of a proportion of mothers with a history of GDM. Likewise, a previous occurrence of either GH, PE, and/or FGR, as well as a previous occurrence of GDM, is associated with the upregulation of miR-1-3p, miR-17-5p, miR-20a-5p, miR-20b-5p, miR-29a-3p, miR-100-5p, miR-125b-5p, miR-126-3p, miR-130b-3p, miR-133a-3p, miR-143-3p, miR-145-5p, miR-146a-5p, miR-181a-5p, miR-199a-5p, miR-221-3p, and miR-499a-5p.

On the other hand, upregulation of miR-16-5p, miR-21-5p, miR-23a-3p, miR-24-3p, miR-26a-5p, miR-103a-3p, miR-195-5p, miR-342-3p, and miR-574-3p represents a unique feature of aberrant expression profile of women with a prior exposure to GDM.

Any changes in epigenome (upregulation of miR-16-5p, miR-17-5p, miR-29a-3p, and miR-195-5p) that were induced by GDM-complicated pregnancy are long-acting and may predispose mothers affected with GDM to later development of diabetes mellitus and cardiovascular/cerebrovascular diseases. In addition, novel epigenetic changes (upregulation of a series of microRNAs) appeared in a proportion of women that were exposed to GDM throughout the postpartal life.

Overall, previous occurrence of GDM, therefore, predisposes a proportion of affected individuals to later development of diabetes mellitus and cardiovascular/cerebrovascular diseases. Screening of particular microRNAs may stratify a high-risk group of mothers with a history of GDM that might benefit from implementation of early primary prevention strategies.

Consecutive large-scale studies, including the groups of mothers on diet only and on the combination of diet and therapy, are needed to verify the findings resulting from this particular pilot study.

6. Patents {#sec6-ijms-21-02437}
==========

National patent granted---Industrial Property Office, Czech Republic (Patent no. 308178).

International patent filed---Industrial Property Office, Czech Republic (PCT/CZ2019/050051).
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GA

Gestational age
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SE

Standard error

NTC

No template control

NAC

No amplification control

![Postpartal microRNA expression profile in mothers with a history of GDM pregnancies. MicroRNA gene expression data (2^−ΔΔCt^) are visualized using the heat map. In this setting, each row represents a sample (GDM1--GDM111, NP1--NP89) and each column represents a microRNA gene. The color and intensity of the boxes are used to represent changes of gene expression (2^−ΔΔCt^). Green color indicates upregulation, and red color indicates downregulation. NP, normal pregnancies.](ijms-21-02437-g001){#ijms-21-02437-f001}

###### 

Postpartal microRNA expression profile in mothers with a history of GDM pregnancies. (**A**--**Z**) Upregulation of miR-1-3p, miR-16-5p, miR-17-5p, miR-20a-5p, miR-20b-5p, miR-21-5p, miR-23a-3p, miR-24-3p, miR-26a-5p, miR-29a-3p, miR-100-5p, miR-103a-3p, miR-125b-5p, miR-126-3p, miR-130b-3p, miR-133a-3p, miR-143-3p, miR-145-5p, miR-146a-5p, miR-181a-5p, miR-195-5p, miR-199a-5p, miR-221-3p, miR-342-3p, miR-499a-5p, and miR-574-3p was observed in mothers after GDM pregnancies when the comparison to the controls was performed using Mann--Whitney test. Receivers operating characteristic (ROC) curves were constructed to calculate the area under the curve (AUC), the best cut-off point (criterion), the sensitivity, specificity, likelihood ratio positive (LR+), and likelihood ratio negative (LR−) for particular microRNA. In addition, respective sensitivity at 90.0% specificity was reported for miR-1-3p (43.24%), miR-16-5p (20.72%), miR-17-5p (21.62%), miR-20a-5p (10.81%), miR-20b-5p (38.74%), miR-21-5p (28.83%), miR-23a-3p (17.12%), miR-24-3p (0.90%), miR-26a-5p (20.72%), miR-29a-3p (21.62%), miR-100-5p (13.51%), miR-103a-3p (30.63%), miR-125b-5p (9.91%), miR-126-3p (9.91%), miR-130b-3p (3.60%), miR-133a-3p (18.92%), miR-143-3p (13.51%), miR-145-5p (7.21%), miR-146a-5p (17.12%), miR-181a-5p (31.53%), miR-195-5p (16.22%), miR-199a-5p (15.32%), miR-221-3p (31.53%), miR-342-3p (1.8%), miR-499a-5p (28.83%), and miR-574-3p (10.81%).
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![Combined postpartal screening of microRNAs in the identification of mothers with a history of GDM at an increased cardiovascular risk. Postpartal combined screening of miR-1-3p, miR-16-5p, miR-17-5p, miR-20b-5p, miR-21-5p, miR-23a-3p, miR-26a-5p, miR-29a-3p, miR-103a-3p, miR-133a-3p, miR-146a-5p, miR-181a-5p, miR-195-5p, miR-199a-5p, miR-221-3p, and miR-499a-5p showed the highest accuracy for the identification of mothers with a prior exposure to GDM at a higher risk of later development of diabetes mellitus, and cardiovascular/cerebrovascular diseases.](ijms-21-02437-g003){#ijms-21-02437-f003}

###### 

Postpartal microRNA expression profile in mothers with a history of GDM pregnancies with regard to the treatment strategies. (**A**--**O**) Upregulation or trend towards upregulation of miR-1-3p, miR-16-5p, miR-17-5p, miR-20b-5p, miR-21-5p, miR-23a-3p, miR-26a-5p, miR-29a-3p, miR-103a-3p, miR-146a-5p, miR-181a-5p, miR-195-5p, miR-199a-5p, miR-221-3p, and miR-499a-5p was observed in mothers after GDM pregnancies regardless of the treatment strategies (diet only and/or the combination of diet and therapy). (**P**) Upregulation of miR-133a-3p was observed in mothers after GDM pregnancies on diet only.
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###### 

The role of differentially expressed microRNAs in mothers with a history of GDM in the pathogenesis of diabetes mellitus, cardiovascular/cerebrovascular diseases.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  miRBase ID        Gene Location on\                                        Role in the Pathogenesis of Cardiovascular/Cerebrovascular Diseases
                    Chromosome                                               
  ----------------- -------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  hsa-miR-1-3p      20q13.3\                                                 Acute myocardial infarction, heart ischemia, post-myocardial infarction complications \[[@B12-ijms-21-02437]\], diabetes mellitus \[[@B13-ijms-21-02437],[@B14-ijms-21-02437]\], vascular endothelial dysfunction \[[@B15-ijms-21-02437]\]
                    18q11.2 \[[@B11-ijms-21-02437]\]                         

  hsa-miR-16-5p     13q14.2                                                  Myocardial infarction \[[@B16-ijms-21-02437],[@B17-ijms-21-02437]\], heart failure \[[@B18-ijms-21-02437]\], acute coronary syndrome, cerebral ischaemic events \[[@B19-ijms-21-02437]\], gestational diabetes mellitus \[[@B20-ijms-21-02437],[@B21-ijms-21-02437]\], diabetes mellitus \[[@B22-ijms-21-02437],[@B23-ijms-21-02437],[@B24-ijms-21-02437]\]

  hsa-miR-17-5p     13q31.3 \[[@B25-ijms-21-02437],[@B26-ijms-21-02437]\]    Cardiac development \[[@B27-ijms-21-02437]\], ischemia/reperfusion-induced cardiac injury \[[@B28-ijms-21-02437]\], kidney ischemia-reperfusion injury \[[@B29-ijms-21-02437]\], diffuse myocardial fibrosis in hypertrophic cardiomyopathy \[[@B30-ijms-21-02437]\], acute ischemic stroke \[[@B31-ijms-21-02437]\], coronary artery disease \[[@B32-ijms-21-02437]\], adipogenic differentiation \[[@B33-ijms-21-02437]\], gestational diabetes mellitus \[[@B20-ijms-21-02437],[@B21-ijms-21-02437]\], diabetes mellitus \[[@B24-ijms-21-02437],[@B34-ijms-21-02437]\]

  hsa-miR-20a-5p    13q31.3 \[[@B35-ijms-21-02437]\]                         Pulmonary hypertension \[[@B36-ijms-21-02437]\], gestational diabetes mellitus \[[@B20-ijms-21-02437],[@B21-ijms-21-02437],[@B37-ijms-21-02437]\], diabetic retinopathy \[[@B38-ijms-21-02437]\], diabetes with abdominal aortic aneurysm \[[@B39-ijms-21-02437]\]

  hsa-miR-20b-5p    Xq26.2 \[[@B35-ijms-21-02437]\]                          Hypertension-induced heart failure \[[@B40-ijms-21-02437]\], insulin resistance \[[@B41-ijms-21-02437]\], T2DM \[[@B42-ijms-21-02437],[@B43-ijms-21-02437]\], diabetic retinopathy \[[@B44-ijms-21-02437]\]

  hsa-miR-21-5p     17q23.2 \[[@B45-ijms-21-02437]\]                         Homeostasis of the cardiovascular system \[[@B46-ijms-21-02437]\], cardiac fibrosis and heart failure \[[@B47-ijms-21-02437],[@B48-ijms-21-02437]\], ascending aortic aneurysm \[[@B49-ijms-21-02437]\], regulation of hypertension-related genes \[[@B50-ijms-21-02437]\], myocardial infarction \[[@B51-ijms-21-02437]\], insulin resistance \[[@B41-ijms-21-02437]\], T2DM \[[@B52-ijms-21-02437]\], T2DM with major cardiovascular events \[[@B53-ijms-21-02437]\], T1DM \[[@B54-ijms-21-02437],[@B55-ijms-21-02437],[@B56-ijms-21-02437]\], diabetic nephropathy \[[@B57-ijms-21-02437]\]

  hsa-miR-23a-3p    19p13.12                                                 Heart failure \[[@B58-ijms-21-02437]\], coronary artery disease \[[@B59-ijms-21-02437]\], cerebral ischemia-reperfusion \[[@B60-ijms-21-02437]\], vascular endothelial dysfunction \[[@B15-ijms-21-02437]\], small and large abdominal aortic aneurysm \[[@B61-ijms-21-02437]\], obesity and insulin resistance \[[@B62-ijms-21-02437]\]

  hsa-miR-24-3p     19p13.12                                                 Asymptomatic carotid stenosis \[[@B63-ijms-21-02437]\], familial hypercholesterolemia and coronary artery disease \[[@B64-ijms-21-02437]\], angina pectoris \[[@B65-ijms-21-02437]\], ischemic dilated cardiomyopathy \[[@B66-ijms-21-02437]\], small and large abdominal aortic aneurysm \[[@B61-ijms-21-02437]\], myocardial ischemia/reperfusion \[[@B67-ijms-21-02437],[@B68-ijms-21-02437]\], diabetes mellitus \[[@B14-ijms-21-02437],[@B24-ijms-21-02437],[@B52-ijms-21-02437],[@B54-ijms-21-02437]\]

  hsa-miR-26a-5p    3p22.2\                                                  Heart failure, cardiac hypertrophy \[[@B70-ijms-21-02437]\], myocardial infarction \[[@B51-ijms-21-02437],[@B71-ijms-21-02437],[@B72-ijms-21-02437]\], ischemia/reperfusion injury \[[@B73-ijms-21-02437]\], pulmonary arterial hypertension \[[@B74-ijms-21-02437]\], T1DM \[[@B75-ijms-21-02437]\], diabetic nephropathy \[[@B57-ijms-21-02437]\]
                    12q14.1 \[[@B69-ijms-21-02437]\]                         

  hsa-miR-29a-3p    7q32.3                                                   Ischemia/reperfusion-induced cardiac injury \[[@B76-ijms-21-02437]\], cardiac cachexia, heart failure \[[@B77-ijms-21-02437]\], atrial fibrillation \[[@B78-ijms-21-02437]\], diffuse myocardial fibrosis in hypertrophic cardiomyopathy \[[@B30-ijms-21-02437]\], coronary artery disease \[[@B79-ijms-21-02437]\], pulmonary arterial hypertension \[[@B74-ijms-21-02437]\], gestational diabetes mellitus \[[@B80-ijms-21-02437]\], diabetes mellitus \[[@B13-ijms-21-02437],[@B23-ijms-21-02437],[@B81-ijms-21-02437],[@B82-ijms-21-02437]\]

  hsa-miR-100-5p    11q24.1                                                  Failing human heart, idiopathic dilated cardiomyopathy, ischemic cardiomyopathy \[[@B66-ijms-21-02437]\], regulation of hypertension-related genes \[[@B50-ijms-21-02437]\], T1DM \[[@B54-ijms-21-02437]\]

  hsa-miR-103a-3p   5q34\                                                    Hypertension \[[@B84-ijms-21-02437]\], hypoxia-induced pulmonary hypertension \[[@B85-ijms-21-02437]\], myocardial ischemia/reperfusion injury, acute myocardial infarction \[[@B84-ijms-21-02437]\], ischemic dilated cardiomyopathy \[[@B66-ijms-21-02437]\], obesity, regulation of insulin sensitivity \[[@B86-ijms-21-02437]\], T1DM \[[@B87-ijms-21-02437]\]
                    20p13 \[[@B83-ijms-21-02437]\]                           

  hsa-miR-125b-5p   11q24.1\                                                 Acute ischemic stroke \[[@B89-ijms-21-02437]\], acute myocardial infarction \[[@B90-ijms-21-02437],[@B91-ijms-21-02437]\], ischemic dilated cardiomyopathy \[[@B66-ijms-21-02437]\], ascending aortic aneurysm \[[@B49-ijms-21-02437]\], gestational diabetes mellitus \[[@B92-ijms-21-02437]\], T1DM \[[@B93-ijms-21-02437],[@B94-ijms-21-02437]\], T2DM \[[@B95-ijms-21-02437]\]
                    21q21.1 \[[@B88-ijms-21-02437]\]                         

  hsa-miR-126-3p    9q34.3 \[[@B96-ijms-21-02437]\]                          Acute myocardial infarction \[[@B72-ijms-21-02437]\], T2DM \[[@B53-ijms-21-02437],[@B97-ijms-21-02437]\], T2DM with major cardiovascular events \[[@B53-ijms-21-02437]\], gestational diabetes mellitus \[[@B98-ijms-21-02437]\]

  hsa-miR-130b-3p   22q11.21                                                 Hypertriglyceridemia \[[@B99-ijms-21-02437],[@B100-ijms-21-02437]\], intracranial aneurysms \[[@B101-ijms-21-02437]\], hyperacute cerebral infarction \[[@B102-ijms-21-02437]\], T2DM \[[@B52-ijms-21-02437],[@B103-ijms-21-02437],[@B104-ijms-21-02437]\], gestational diabetes mellitus \[[@B98-ijms-21-02437]\]

  hsa-miR-133a-3p   18q11.2\                                                 Heart failure \[[@B106-ijms-21-02437]\], myocardial fibrosis in hypertrophic cardiomyopathy \[[@B30-ijms-21-02437],[@B107-ijms-21-02437]\], arrhythmogenesis in the hypertrophic and failing hearts \[[@B108-ijms-21-02437],[@B109-ijms-21-02437]\], coronary artery calcification \[[@B110-ijms-21-02437]\], ascending aortic aneurysm \[[@B49-ijms-21-02437]\], diabetes mellitus \[[@B13-ijms-21-02437],[@B14-ijms-21-02437]\]
                    20q13.33 \[[@B105-ijms-21-02437]\]                       

  hsa-miR-143-3p    5q33                                                     Intracranial aneurysms \[[@B111-ijms-21-02437]\], coronary heart disease \[[@B112-ijms-21-02437]\], myocardial infarction \[[@B113-ijms-21-02437]\], myocardial hypertrophy \[[@B114-ijms-21-02437]\], dilated cardiomyopathy \[[@B115-ijms-21-02437]\], pulmonary arterial hypertension \[[@B116-ijms-21-02437]\], acute ischemic stroke \[[@B89-ijms-21-02437]\], ascending aortic aneurysm \[[@B49-ijms-21-02437]\]

  hsa-miR-145-5p    5q33                                                     Hypertension \[[@B117-ijms-21-02437],[@B118-ijms-21-02437]\], dilated cardiomyopathy \[[@B119-ijms-21-02437]\], myocardial infarction \[[@B120-ijms-21-02437],[@B121-ijms-21-02437]\], stroke \[[@B121-ijms-21-02437]\], acute cerebral ischemic/reperfusion \[[@B122-ijms-21-02437]\], T2DM \[[@B24-ijms-21-02437],[@B123-ijms-21-02437]\], T1DM \[[@B52-ijms-21-02437]\], diabetic retinopathy \[[@B124-ijms-21-02437]\], gestational diabetes mellitus \[[@B125-ijms-21-02437]\]

  hsa-miR-146a-5p   5q33.3 \[[@B126-ijms-21-02437],[@B127-ijms-21-02437]\]   Angiogenesis \[[@B128-ijms-21-02437]\], hypoxia, ischemia/reperfusion-induced cardiac injury \[[@B129-ijms-21-02437]\], myocardial infarction \[[@B17-ijms-21-02437]\], coronary atherosclerosis, coronary heart disease in patients with subclinical hypothyroidism \[[@B130-ijms-21-02437]\], acute ischemic stroke, acute cerebral ischemia \[[@B131-ijms-21-02437]\], T2DM \[[@B24-ijms-21-02437],[@B52-ijms-21-02437]\], T1DM \[[@B75-ijms-21-02437]\], diabetic nephropathy \[[@B57-ijms-21-02437]\]

  hsa-miR-181a-5p   1q32.1\                                                  Regulation of hypertension-related genes \[[@B50-ijms-21-02437]\], atherosclerosis \[[@B132-ijms-21-02437]\], metabolic syndrome, coronary artery disease \[[@B133-ijms-21-02437]\], non-alcoholic fatty liver disease \[[@B134-ijms-21-02437]\], ischaemic stroke, transient ischaemic attack, acute myocardial infarction \[[@B135-ijms-21-02437],[@B136-ijms-21-02437]\], obesity and insulin resistance \[[@B62-ijms-21-02437],[@B132-ijms-21-02437],[@B133-ijms-21-02437]\], T1DM \[[@B52-ijms-21-02437],[@B137-ijms-21-02437]\], T2DM \[[@B132-ijms-21-02437],[@B136-ijms-21-02437]\]
                    9q33.3 \[[@B132-ijms-21-02437]\]                         

  hsa-miR-195-5p    17p13.1 \[[@B138-ijms-21-02437]\]                        Cardiac hypertrophy, heart failure \[[@B139-ijms-21-02437],[@B140-ijms-21-02437]\], abdominal aortic aneurysms \[[@B141-ijms-21-02437]\], aortic stenosis \[[@B142-ijms-21-02437]\], T2DM \[[@B123-ijms-21-02437]\], gestational diabetes mellitus \[[@B143-ijms-21-02437]\]

  hsa-miR-199a-5p   1q24.3\                                                  Hypertension \[[@B144-ijms-21-02437]\], congenital heart disease \[[@B145-ijms-21-02437]\], pulmonary artery hypertension \[[@B146-ijms-21-02437]\], unstable angina \[[@B147-ijms-21-02437]\], diabetic retinopathy \[[@B148-ijms-21-02437]\], T1DM, T2DM, gestational diabetes mellitus \[[@B149-ijms-21-02437]\]
                    19p13.2                                                  

  hsa-miR-221-3p    Xp11.3                                                   Asymptomatic carotid stenosis \[[@B63-ijms-21-02437]\], cardiac amyloidosis \[[@B150-ijms-21-02437]\], heart failure \[[@B151-ijms-21-02437]\], atherosclerosis \[[@B152-ijms-21-02437],[@B153-ijms-21-02437]\], aortic stenosis \[[@B154-ijms-21-02437]\], acute myocardial infarction \[[@B155-ijms-21-02437]\], acute ischemic stroke \[[@B156-ijms-21-02437]\], focal cerebral ischemia \[[@B157-ijms-21-02437]\], pulmonary artery hypertension \[[@B158-ijms-21-02437]\], obesity \[[@B159-ijms-21-02437]\]

  hsa-miR-342-3p    14q32.2                                                  Cardiac amyloidosis \[[@B150-ijms-21-02437]\], obesity \[[@B160-ijms-21-02437]\], T1DM \[[@B52-ijms-21-02437],[@B149-ijms-21-02437],[@B161-ijms-21-02437]\], T2DM \[[@B149-ijms-21-02437],[@B162-ijms-21-02437],[@B163-ijms-21-02437]\], GDM \[[@B149-ijms-21-02437]\], endothelial dysfunction \[[@B164-ijms-21-02437]\]

  hsa-miR-499a-5p   20q11.22                                                 Myocardial infarction \[[@B17-ijms-21-02437],[@B165-ijms-21-02437]\], hypoxia \[[@B166-ijms-21-02437]\], cardiac regeneration \[[@B167-ijms-21-02437]\], vascular endothelial dysfunction \[[@B15-ijms-21-02437]\]

  hsa-miR-574-3p    4p14                                                     Myocardial infarction \[[@B168-ijms-21-02437]\], coronary artery disease \[[@B100-ijms-21-02437]\], cardiac amyloidosis \[[@B150-ijms-21-02437]\], stroke \[[@B169-ijms-21-02437]\], T2DM \[[@B104-ijms-21-02437],[@B170-ijms-21-02437]\]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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###### 

A list of predicted targets of appropriate microRNAs dysregulated in whole peripheral blood of patients with a history of GDM in relation to insulin signaling pathway using miRWalk2.0 database.

  microRNA      Predicted Targets
  ------------- --------------------------------------------------------------------------------------------------
  miR-1         CALM2, CBL, IKBKB, KRAS, PHKG2, PIK3R5, PTPN1, PTPRF, TRIP10
  miR-16-5p     IKBKB, PHKA1, PRKAR1A, MAP2K1, RAF1, IRS4, MKNK1, EXOC7, FASN
  miR-17-5p     PHKA2, CRK, GRB2, PDE3A, PHKG1, PIK3R2, PRKAA2, PRKAR2A, MAPK9, PRKX, PPP1R3B, HK1, PCK1, SREBF1
  miR-20a-5p    BRAF, MKNK2, CRK, SLC2A4, TRIP10, KRAS, PCK1
  miR-20b-5p    CRK, GRB2, PDE3A, PHKA2, PHKG1, PIK3R2, PRKAA2, PRKAR2A, MAPK9, PRKX, PPP1R3B, HK1, PCK1, SREBF1
  miR-21-5p     PPP1R3A, PPP1R3D
  miR-23a-3p    G6PC, IRS2, IKBKB, PIK3CB, FASN, PRKAG3
  miR-24-3p     IKBKB, PIK3CB, PTPRF, SHC2, INPP5K, PHKG1, PRKAG3
  miR-26a-5p    G6PC, MKNK2, GYS2, PPP1R3D, RHOQ, KRAS, PRKAG1, PYGL
  miR-29a-3p    NRAS, EIF4E2, CALM3
  miR-100-5p    MTOR
  miR-103a-3p   FAS, RAPGEF1, PDE3B, ACACB, PHKAR1A, PRKCI, IRS2, LIPE, PRKC2, MAPK3, TRIP10, CBLC, CALML5
  miR-125b-5p   PHKA1, RAF1, ACACB, FLOT2, HK2, EIF4E2, PHKG1
  miR-126-3p    TSC1
  miR-130b-3p   RPS6KB1, MAP2K1, SOS2, FLOT2, EXOC7, PHKG2, PIK3CA, PRKC2, TSC2, PRKAG3
  miR-133a-3p   PRKAB1
  miR-143-3p    FOXO1, KRAS, HK2, PHKG2, MAPK3, MAPK9, SREBF1
  miR-145-5p    IRS1, IRS2, PIK3R5, PRKAG3
  miR-181a-5p   NRAS, AKT3, SOCS4, HK2, PDE3B, PPP1R3C, PRKAR2A, MAPK1, PPP1R3D, PRKAA1
  miR-195-5p    IKBKB, PHKA1, PRKAR1A, MAP2K1, RAF1, IRS4, MKNK1, EXOC7, FASN
  miR-199a-5p   PRKX, PCK1, IRS1, SLC2A4, MAPK9, RHEB, PRKAR1A
  miR-221-3p    AKT3, PIK3CD, MAPK10
  miR-342-3p    PDPK1, INSR, PHKG2, EIF4E2, PIK3CD, RPS6KB2
  miR-499a-5p   AKT2, CRK, KRAS, PIK3CD, PRKAR1A, SOS2
  miR-574-3p    PRKCZ, HK1
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###### 

A list of predicted targets of appropriate microRNAs dysregulated in whole peripheral blood of patients with a history of GDM in relation to type 1 diabetes mellitus pathway using miRWalk2.0 database.

  microRNA      Predicted Targets
  ------------- -----------------------------------------------
  miR-1         CD28, LTA
  miR-16-5p     HLA-DQA1
  miR-17-5p     FASLG, CD28, HLA-DQA, GAD2, HLA-DPA1
  miR-20a-5p    IL12A
  miR-20b-5p    HLA-DOA, FASLG, CD28, HLA-DPA1, GAD2
  miR-21-5p     HLA-DPB1, FASLG, IL12A
  miR-23a-3p    IFNG
  miR-24-3p     CD28, CD86, IFNG, FASLG, IL1B, HLA-DOA
  miR-26a-5p    HLA-DPB1, HLA-DPA1, HLA-A, IFNG
  miR-29a-3p    HLA-DQA2
  miR-103a-3p   HLA-DPB1, CD80
  miR-125b-5p   PRF-1
  miR-130b-3p   HLA-DOA, HLA-DQB1, HLA-A, HLA-B, HLA-C, HLA-G
  miR-133a-3p   HLA-DOA, CD28, GAD2, LTA
  miR-143-3p    HLA-DOA, HLA-DPB1, HLA-DPA1, IFNG, CD28
  miR-146a-5p   CD80, CD86, PRF1, ICA1, HLA-C, GAD2
  miR-181a-5p   IL2, HLA-E, IL1A
  miR-195-5p    HLA-DQA1
  miR-199a-5p   G2MB, ICA1,TNF
  miR-221-3p    HLA-DQA1, PTPRN
  miR-342-3p    PTPRN2, HLA-A, HLA-F
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###### 

A list of predicted targets of appropriate microRNAs dysregulated in whole peripheral blood of patients with a history of GDM in relation to type 2 diabetes mellitus pathway using miRWalk2.0 database.

  microRNA      Predicted Targets
  ------------- ----------------------------------------
  miR-16-5p     CACNA1E, IKBKB, IRS4
  miR-17-5p     PIK3R2, MAPK9, HK1
  miR-20a-5p    SLC2A4
  miR-20b-5p    MAPK9, HK1
  miR-23a-3p    IRS2, IKBKB, PIK3CB
  miR-24-3p     IKBKB, PIK3CB, KCNJ11
  miR-26a-5p    PRKCD
  miR-29a-3p    CACNA1A, CACNA1B
  miR-100-5p    MTOR
  miR-103a-3p   CACNA1E, IRS2, PRKCZ, MAPK3
  miR-125b-5p   HK2
  miR-130b-3p   PIK3CA, PRKCZ
  miR-143-3p    CACNA1A, HK2, PRKCE, MAPK3, MAPK9
  miR-145-5p    IRS2, IRS1, PIK3R5
  miR-146a-5p   PRKCE
  miR-181a-5p   SOCS4, HK2, MAPK1
  miR-195-5p    CACNA1E, IKBKB, IRS4
  miR-199a-5p   IRS1, SLC2A4, MAPK9, PKM, TNF, CACNA1G
  miR-221-3p    PIK3CD, MAPK10
  miR-342-3p    CACNA1C, INSR, PIK3CD
  miR-499a-5p   PRKCE, PIK3CD
  miR-574-3p    PRKCZ, HK1

The miRWalk database and the predicted target module were used to provide information on predicted interactions between appropriate microRNAs and specific genes involved in human biological pathways such as insulin signaling, type 1 diabetes mellitus, and type 2 diabetes mellitus.
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###### 

Characteristics of cases and controls, pre-existing cardiovascular risk factors before gestation.

  ----------------------------------------------------------------------------------------------------------------------------------------------------
                                                        Normotensive Term Pregnancies\   GDM on Diet Only\                GDM on Diet and Therapy\
                                                        (*n* = 89)                       (*n* = 93)                       (*n* = 18)
  ----------------------------------------------------- -------------------------------- -------------------------------- ----------------------------
  Rheumatoid arthritis                                  0 (0%)                           1 (1.08%)                        0 (0%)

  SLE                                                   0 (0%)                           0 (0%)                           0 (0%)

  On blood pressure treatment                           0 (0%)                           0 (0%)                           0 (0%)

  Hypercholesterolemia                                  0 (0%)                           1 (1.08%)                        0 (0%)

  Dispensarisation at Dpt. of Cardiology\               0 (0%)                           4 (4.30%)\                       1 (5.55%)\
  (valve problems and heart defects)                                                     Mitral valve prolapse\           Mitral valve regurgitation
                                                                                         Heart arrhythmia\                
                                                                                         Hypertrophic cardiomyopathy\     
                                                                                         AV nodal reentrant tachycardia   

  Chronic venous insufficiency                          0 (0%)                           0 (0%)                           0 (0%)

  Thrombosis                                            0 (0%)                           2 (2.15%)                        0 (0%)

  Presence of risk factors for chronic kidney disease   0 (%)                            6 (6.45%)\                       0 (0%)
                                                                                         Pyelonephritis\                  
                                                                                         Glomerulonephritis\              
                                                                                         Ureteral stent\                  
                                                                                         Nephrolithiasis\                 
                                                                                         Hydronephrosis                   

  Chronic kidney disease                                0 (%)                            1 (0.98%)\                       0 (0%)
                                                                                         Chronic renal insufficiency      
  ----------------------------------------------------------------------------------------------------------------------------------------------------
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###### 

Characteristics of cases and controls, data gained at follow-up.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                 Normotensive Term Pregnancies\   GDM on Diet Only\             GDM on Diet and Therapy\   *p*-value^1^   *p*-value^2^
                                                                                 (*n* = 89)                       (*n* = 93)                    (*n* = 18)                                
  ------------------------------------------------------------------------------ -------------------------------- ----------------------------- -------------------------- -------------- --------------
  Age (years)                                                                    38.33 ± 0.38                     38.70 ± 0.37                  38.61 ± 0.80               0.465          0.564

  Time elapsed since delivery (years)                                            5.75 ± 0.20                      5.49 ± 0.12                   5.33 ± 0.20                0.965          0.045

  BMI                                                                            23.15 ± 0.38                     23.85 ± 0.37                  27.21 ± 0.83               1.000          1.000

  Normal (\< 25)                                                                 67 (75.28%)                      70 (75.27%)                   5 (27.78%)                 0.633          \< 0.001

  Overweight (≥ 25 \<30)                                                         18 (20.22%)                      16 (17.20%)                   9 (50.00%)                                

  Obese (≥ 30)                                                                   4 (4.49%)                        7 (7.53%)                     4 (22.22%)                                

  Smoking                                                                        \-                               \-                                                                      

  Non-Smoker                                                                     54 (60.67%)                      78 (83.87%)                   16 (88.88%)                               

  Ex-smoker                                                                      21 (23.60%)                      6 (6.45%)                     2 (11.11%)                                

  Smoker                                                                         14 (15.73%)                      9 (9.68%)                     0 (0%)                                    

  Angina or heart attack in a first degree relative before the age of 60 years   2 (2.22%)                        6 (6.45%)                     2 (11.11%)                 \-             \-

  Atrial fibrillation                                                            0 (0%)                           0 (0%)                        0 (0%)                     \-             \-

  DM type I                                                                      0 (0%)                           0 (0%)                        0 (0%)                     \-             \-

  DM type II                                                                     0 (0%)                           0 (0%)                        0 (0%)                     \-             \-

  Fasting serum glucose levels                                                   \-                               \-                                                                      

  Normal (3.33--5.59 mmol/L)                                                     89 (100.0%)                      90 (96.77%)                   18 (100.0%)                               

  High (\> 5.59 mmol/L)                                                          0 (0%)                           3 (3.23%)                     0 (0%)                                    

  Fasting serum total cholesterol levels                                         \-                               \-                                                                      

  Normal (2.9--5.0 mmol/L)                                                       43 (48.31%)                      51 (54.84%)                   10 (55.55%)                               

  High (\> 5.0--7.9 mmol/L)                                                      46 (51.69%)                      41(44.09%)                    8 (44.44%)                                

  Critical (≥ 8.0 mmol/L)                                                        0 (0%)                           1 (1.08%)                     0 (0%)                                    

  Fating serum LDL cholesterol levels                                            0.987                            0.281                                                                   

  Normal (1.2--3.0 mmol/L)                                                       42 (47.19%)                      44 (47.31%)                   6 (33.33%)                                

  High (\> 3.0 mmol/L)                                                           47 (52.81%)                      49 (52.69%)                   12 (66.67%)                               

  SBP                                                                            \-                               \-                                                                      

  Normal (\< 140 mmHg)                                                           89 (100.0%)                      92 (98.92%)                   18 (100.0%)                               

  High (≥ 140--179 mmHg)                                                         0 (0%)                           1 (1.08%)                     0 (0%)                                    

  Critical (≥ 180 mmHg)                                                          0 (0%)                           0 (0%)                        0 (0%)                                    

  DBP                                                                            \-                               \-                                                                      

  Normal (\< 90 mmHg)                                                            88 (98.88%)                      90 (96.77%)                   17 (94.44%)                               

  High (≥ 90--109 mmHg)                                                          1 (1.12%)                        3 (3.23%)                     1 (5.56%)                                 

  Critical (≥ 110 mmHg)                                                          0 (0%)                           0 (0%)                        0 (0%)                                    

  On blood pressure treatment                                                    0 (0%)                           0 (0%)                        0 (0%)                     \-             \-

  Chronic kidney disease                                                         0 (%)                            1 (0.98%)\                    0 (0%)                     \-             \-
                                                                                                                  Chronic renal insufficiency                                             

  Chronic venous insufficiency                                                   0 (0%)                           0 (0%)                        0 (0%)                     \-             \-

  Thrombosis                                                                     0 (0%)                           2 (2.15%)                     0 (0%)                     \-             \-

  Relative QRISK^®^3-2018 risk score                                             0.926 ± 0.05                     0.889 ± 0.04                  1.022 ± 0.08               1.0            1.0

  Hormonal contraceptive use                                                     0.040                            0.474                                                                   

  No                                                                             12 (13.48%)                      5 (5.38%)                     2 (11.11%)                                

  In the past                                                                    63 (70.79%)                      80 (86.02%)                   15 (83.33%)                               

  Yes                                                                            14 (15.73%)                      8 (8.60%)                     1 (5.56%)                                 

  Total number of pregnancies per patient                                        0.924                            0.440                                                                   

  1                                                                              9 (10.11%)                       8 (8.60%)                     2 (11.11%)                                

  2                                                                              44 (49.44%)                      48 (51.61%)                   6 (33.33%)                                

  3+                                                                             36 (40.45%)                      37 (39.78%)                   10 (55.55%)                               

  Total parity per patient                                                       0.991                            0.217                                                                   

  1                                                                              13 (14.61%)                      13 (13.98%)                   2 (11.11%)                                

  2                                                                              62 (69.66%)                      65 (69.89%)                   10 (55.55%)                               

  3+                                                                             14 (15.73%)                      15 (16.13%)                   6 (33.33%)                                
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data are presented as mean ± SE for continuous variables and as number (percent) for categorical variables. Statistically significant results are marked in bold. Continuous variables were compared using Mann--Whitney test. *p*-value^1^, the comparison among normal pregnancies and GDM on diet; *p*-value^2^, the comparison among normal pregnancies and GDM on diet and therapy, respectively. Categorical variables were compared using a chi-square test. GA, gestational age; SBP, systolic blood pressure; DBP, diastolic blood pressure; CS, caesarean section.
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###### 

Characteristics of cases and controls, data gained during gestation.

  -----------------------------------------------------------------------------------------------------------------------------------------
                              Normotensive Term Pregnancies\   GDM on Diet Only\   GDM on Diet and Therapy\   *p*-value^1^   *p*-value^2^
                              (*n* = 89)                       (*n* = 93)          (*n* = 18)                                
  --------------------------- -------------------------------- ------------------- -------------------------- -------------- --------------
  Maternal age at delivery\   32.62 ± 0.36                     33.20 ± 0.35        33.28 ± 0.83               0.111          1.000
  (years)                                                                                                                    

  GA at delivery (weeks)      39.90 ± 0.10                     39.59 ± 0.09        39.20 ± 0.23               0.961          1.000

  Fetal birth weight (g)      3397.53 ± 40.42                  3436.56 ± 35.96     3526.11 ± 63.35            1.000          1.000

  Mode of delivery            \< 0.001                         0.015                                                         

  Vaginal                     82 (92.13%)                      57 (61.29%)         13 (72.22%)                               

  CS                          7 (7.87%)                        36 (38.71%)         5 (27.78%)                                

  Fetal sex                   0.476                            0.281                                                         

  Boy                         47 (52.81%)                      54 (58.06%)         12 (66.67%)                               

  Girl                        42 (47.19%)                      39 (41.94%)         6 (33.33%)                                

  Infertility treatment       0.006                            0.846                                                         

  Yes                         4 (4.49%)                        16 (17.20%)         1 (5.56%)                                 

  No                          85 (95.51%)                      77 (82.80%)         17 (94.44%)                               
  -----------------------------------------------------------------------------------------------------------------------------------------

Data are presented as mean ± SE for continuous variables and as number (percent) for categorical variables. Statistically significant results are marked in bold. Continuous variables were compared using Mann--Whitney test. *p*-value^1^, the comparison among normal pregnancies and GDM on diet; *p*-value^2^, the comparison among normal pregnancies and GDM on diet and therapy, respectively. Categorical variables were compared using a chi-square test. GA, gestational age; SBP, systolic blood pressure; DBP, diastolic blood pressure; CS, caesarean section.
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###### 

Characteristics of microRNAs involved in the study.

  Assay Name       miRBase ID        NCBI Location Chromosome           microRNA Sequence
  ---------------- ----------------- ---------------------------------- -------------------------------
  hsa-miR-1        hsa-miR-1-3p      Chr20: 61151513-61151583 \[+\]     5´-UGGAAUGUAAAGAAGUAUGUAU-3´
  hsa-miR-16       hsa-miR-16-5p     Chr13: 50623109-50623197 \[−\]     5´-UAGCAGCACGUAAAUAUUGGCG- 3´
  hsa-miR-17       hsa-miR-17-5p     Chr13: 92002859-92002942 \[+\]     5´-CAAAGUGCUUACAGUGCAGGUAG-3´
  hsa-miR-20a      hsa-miR-20a-5p    Chr13: 92003319-92003389 \[+\]     5´-UAAAGUGCUUAUAGUGCAGGUAG-3´
  hsa-miR-20b      hsa-miR-20b-5p    ChrX: 133303839-133303907 \[−\]    5´-CAAAGUGCUCAUAGUGCAGGUAG-3´
  hsa-miR-21       hsa-miR-21-5p     Chr17: 57918627-57918698 \[+\]     5´-UAGCUUAUCAGACUGAUGUUGA-3´
  hsa-miR-23a      hsa-miR-23a-3p    Chr19: 13947401-13947473 \[−\]     5´-AUCACAUUGCCAGGGAUUUCC-3´
  hsa-miR-24       hsa-miR-24-3p     Chr19: 13947101-13947173 \[−\]     5´-UGGCUCAGUUCAGCAGGAACAG-3´
  hsa-miR-26a      hsa-miR-26a-5p    Chr3: 38010895-38010971 \[+\]      5´-UUCAAGUAAUCCAGGAUAGGCU-3´
  hsa-miR-29a      hsa-miR-29a-3p    Chr7: 130561506-130561569 \[−\]    5´-UAGCACCAUCUGAAAUCGGUUA-3´
  hsa-miR-92a      hsa-miR-92a-3p    Chr13: 92003568-92003645 \[+\]     5´-UAUUGCACUUGUCCCGGCCUGU-3´
  hsa-miR-100      hsa-miR-100-5p    Chr11: 122022937-122023016 \[−\]   5´-AACCCGUAGAUCCGAACUUGUG-3´
  hsa-miR-103      hsa-miR-103a-3p   Chr20: 3898141-3898218 \[+\]       5´-AGCAGCAUUGUACAGGGCUAUGA-3´
  hsa-miR-125b     hsa-miR-125b-5p   Chr21: 17962557-17962645 \[+\]     5´-UCCCUGAGACCCUAACUUGUGA-3´
  hsa-miR-126      hsa-miR-126-3p    Chr9: 139565054-139565138 \[+\]    5´-UCGUACCGUGAGUAAUAAUGCG-3´
  hsa-miR-130b     hsa-miR-130b-3p   Chr22: 22007593-22007674 \[+\]     5´-CAGUGCAAUGAUGAAAGGGCAU-3´
  hsa-miR-133a     hsa-miR-133a-3p   Chr20: 61162119-61162220 \[+\]     5´-UUUGGUCCCCUUCAACCAGCUG-3´
  hsa-miR-143      hsa-miR-143-3p    Chr5: 148808481-148808586 \[+\]    5´-UGAGAUGAAGCACUGUAGCUC-3´
  hsa-miR-145      hsa-miR-145-5p    Chr5: 148810209-148810296 \[+\]    5´-GUCCAGUUUUCCCAGGAAUCCCU-3´
  hsa-miR-146a     hsa-miR-146a-5p   Chr5: 159912359-159912457 \[+\]    5´-UGAGAACUGAAUUCCAUGGGUU-3´
  hsa-miR-155      hsa-miR-155-5p    Chr21: 26946292-26946356 \[+\]     5´-UUAAUGCUAAUCGUGAUAGGGGU-3´
  hsa-miR-181a     hsa-miR-181a-5p   Chr9: 127454721-127454830 \[+\]    5´-AACAUUCAACGCUGUCGGUGAGU-3´
  hsa-miR-195      hsa-miR-195-5p    Chr17: 6920934-6921020 \[−\]       5´-UAGCAGCACAGAAAUAUUGGC-3´
  hsa-miR-199a     hsa-miR-199a-5p   Chr19: 10928102-10928172 \[−\]     5´-CCCAGUGUUCAGACUACCUGUUC-3´
  hsa-miR-210      hsa-miR-210-3p    Chr11: 568089-568198 \[−\]         5´-CUGUGCGUGUGACAGCGGCUGA-3´
  hsa-miR-221      hsa-miR-221-3p    ChrX: 45605585-45605694 \[−\]      5´-AGCUACAUUGUCUGCUGGGUUUC-3´
  hsa-miR-342-3p   hsa-miR-342-3p    Chr14: 100575992-100576090 \[+\]   5´-UCUCACACAGAAAUCGCACCCGU-3´
  mmu-miR-499      hsa-miR-499a-5p   Chr20: 33578179-33578300 \[+\]     5´-UUAAGACUUGCAGUGAUGUUU-3´
  hsa-miR-574-3p   hsa-miR-574-3p    Chr4: 38869653-38869748 \[+\]      5´-CACGCUCAUGCACACACCCACA-3´
